| dc.description.abstract | Klebsiella pneumoniae is one of the most common causes of infections worldwide, second only to Escherichia coli. Due to the problem of overuse of antibiotics, cases
of multiple antibiotic resistance and production rates of broad – spectrum β –
lactamase (ESBL) and β – lactamase AmpC are constantly growing rapidly and with
concern. This study was conducted with the purpose of investigating the antibiotic
resistance and ESBL and AmpC positive rates of Klebsiella pneumoniae isolates
isolated from patient samples sent to the Clinical Microbiology laboratory in Nam
Khoa Trading and Service Co., Ltd. The method used to conduct this process is a
cross – sectional study. Microsoft Excel 2019 software was used to analyze the
collected data. From January 2022 to January 2023, there were a total of 1018 patient
samples with the infectious agent Klebsiella pneumoniae in four groups of specimens
(sputum, blood, pus – fluid and urine). With the following results: Klebsiella
pneumoniae was most resistant to Ampicillin (98%), followed by
Amoxicillin/clavulanic acid (57%), Ciprofloxacin and Tetracycline (both 56%), Cefotaxime (55%), Trimethoprim/sulfamethoxazole (53%) and Cefoxitin (50%). Only a small percentage showed resistance to Imipenem (25%), Nitrofurantoin
(25%), and Colistin (27%). In addition, 9% of the samples produced ESBL and 13%
of the samples produced AmpC. From the results obtained, the choice of antibiotic
must be appropriate to the situation of each patient so that multidrug resistance can
be avoided. | en_US |
